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RETINAL DISORDERS
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Abstract
Purpose To report the effectiveness of intravitreal aflibercept (IVT-AFL) treatment for diabetic macular edema (DME) in French
clinical practice.
Methods APOLLON (NCT02924311) was a prospective, observational cohort study of patients with DME. Effectiveness was
evaluated by change from baseline in best-corrected visual acuity (BCVA) at 12 months in treatment-naïve patients (i.e., had not
received any anti-vascular endothelial growth factor [anti-VEGF] agent, laser, or steroid at IVT-AFL treatment start) and
previously treated patients (i.e., previously treated with anti-VEGF agents other than IVT-AFL, laser, or steroids at IVT-AFL
treatment start). Secondary endpoints included change in central retinal thickness (CRT) over 12 months, frequency of injections,
and proportion of patients with safety events.
Results Of the 147 patients followed for at least 12 months and included in the effectiveness analysis, 52.4% (n = 77) were
treatment-naïve and 47.6% (n = 70) were previously treated. Mean (standard deviation [SD]) BCVA score at baseline was 62.7
(14.3) Early Treatment Diabetic Retinopathy Study (ETDRS) letters in treatment-naïve patients and 60.0 (13.7) ETDRS letters in
previously treated patients. At month 12, mean (SD) change in BCVAwas + 7.8 (12.3) letters in treatment-naïve patients and +
5.0 (11.3) letters in previously treated patients. Mean CRT decreased in both patient cohorts. The mean (SD) number of IVT-AFL
injections at month 12 was 7.6 (2.5) for treatment-naïve patients and 7.6 (2.3) for previously treated patients. Of 388 patients
included in the safety analysis, ocular treatment-emergent adverse events occurred in 54.1% (n = 210) of patients.
Conclusion IVT-AFL treatment was associated with improvements in functional and anatomic outcomes in both treatment-naïve
and previously treated patients with DME in France.
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Introduction
Diabetic macular edema (DME) is a complication of dia-
betic retinopathy and manifests as retinal thickening from
the accumulation of intraretinal fluid (IRF) caused by fail-
ure of the blood–retinal barrier [1]. DME is the leading
cause of visual impairment in patients with diabetes [2]
and its rate is expected to rise in the next decade due to
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the substantial increase in worldwide incidence of diabetes
[3]. The Wisconsin Epidemiologic Study of Diabetic
Retinopathy reported that the incidence of DME in patients
with type 1 or type 2 diabetes doubled within 5–6 years of
disease diagnosis [4].
Anti-vascular endothelial growth factor (anti-VEGF)
agents, such as intravitreal aflibercept (IVT-AFL) and
ranibizumab, are recommended as first-line therapy for
DME [1]; their use is based on the observation that VEGF
levels are increased in the retina of patients with retinopathies
and that VEGF acts as an important mediator of the blood–
retinal barrier breakdown [5, 6]. Results from the phase 3
VISTA-DME and VIVID-DME studies showed that IVT-
AFL treatment was associated with statistically significant
improvements in visual outcomes compared with laser [7].
The efficacy demonstrated in clinical trials does not always
reflect the effectiveness achieved in a real-world setting due to
selection biases in the former and poor adherence in the latter.
Therefore, real-world studies are useful in showing the effec-
tiveness of anti-VEGF agents in DME management in current
clinical settings.
APOLLON was a prospective, observational study that
evaluated the effectiveness of IVT-AFL treatment in patients
with DME in French clinical practice over a period of
24months. Here, we report functional and anatomic outcomes




APOLLON (NCT02924311) was a prospective, multicentre,
observational cohort study of patients with DME conducted in
French private and public ophthalmological clinics and prac-
tices between September 2016 and July 2019. Data were col-
lected during clinical visits at baseline; after each IVT-AFL
treatment in the first 5 months; and at 6, 12, and 24 months
post-treatment start in treatment-naïve patients and previously
treated patients (previously treated with an anti-VEGF agent
(other than IVT-AFL), laser, or steroids at IVT-AFL treatment
start).
This study was conducted in accordance with the
International Conference on Harmonisation guidelines for
Good Clinical Practice and the ethical principles of the 1964
Declaration of Helsinki and its later amendments or compara-
ble ethical standards. The study protocol and informed con-
sent forms were reviewed and approved by the French
Consultative Committee on the Processing of Information in
Health Research and by the French National Medical Council
prior to any patient being enrolled into the study.
Endpoints
The primary endpoint was change from baseline in best-
corrected visual acuity (BCVA) at 12 months in the treat-
ment-naïve cohort and the previously treated cohort.
Secondary endpoints included the change from baseline in
BCVA in the whole population at 12months, change in central
retinal thickness (CRT) between baseline and 12-month fol-
low-up for all cohorts, frequency of injections over 12months,
and proportion of patients with safety events.
Patients
Patients aged ≥ 18 years with type 1 or type 2 diabetes diag-
nosed with baseline visual acuity ≤ 5/10 (≤ 20/40) due to
DME were included. Patients with other retinal disease who
were already in treatment with IVT-AFL, taking part in an
interventional study, or using any anti-VEGF therapy were
excluded. To reduce selection biases, patients were recruited
in a consecutive manner. Patients could withdraw from the
study at any time or could be withdrawn at the discretion of
the investigator or sponsor for safety, behavioural, or admin-
istrative reasons.
Variables
BCVA was recorded using Early Treatment Diabetic
Retinopathy Study (ETDRS) scores or Snellen chart convert-
ed to approximate ETDRS letter scores [8].
Statistical analysis
Demographic information, medical history, and clinical char-
acteristics were collected by treating ophthalmologists or
medical staff from available medical records and at the time
of follow-up. For the 2-year APOLLON study, a sample size
of 385 patients was calculated to produce a two-sided 95%
confidence interval with a distance from the mean to the limits
equal to 1099 when the known standard deviation (SD) is
11,000.
For the effectiveness analysis, continuous variables were
presented as mean (SD) and categorical variables as numbers
and percentages. The last observation carried forward method
or the median of the population was used to replace missing
data. All statistical calculations were performed with SAS
version 9.2 or higher (SAS Institute Inc., Cary, NC, USA).
The safety analysis was conducted on the safety set compris-
ing all patients who received at least one IVT-AFL injection.
Treatment-emergent adverse events (TEAEs) were
summarised using the Medical Dictionary for Regulatory
Activities coding system.
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Results
Baseline characteristics
Of the 402 patients with DME enrolled in the study, 374 pa-
tients were included in the full analysis set and 388 patients
were included in the safety analysis (Fig. 1). Of the 147 patients
who were followed for at least 12 months at the time of this
analysis, 52.4% (n = 77) were treatment-naïve and 47.6% (n =
70) were previously treated. Of the patients who were followed
for at least 12 months, six patients terminated the study prema-
turely (i.e., terminated the study before 24 ± 1 months), five
patients discontinued due to switching to another treatment,
and one patient changed their treating physician. The main
reasons for switching treatment were lack of efficacy (n = 2)
and decision of the treating ophthalmologist (n = 3).
Baseline demographic and clinical characteristics are pro-
vided in Table 1. Overall, 55.8% of patients were male, the
mean age was 65.8 years, and the median time (quartile 1;
quartile 3) since last treatment in the previously treated cohort
was 3.1 (1.5; 6.9) months. The visual and anatomic character-
istics are provided in Table 1.Mean (SD) BCVAETDRS letter
score was 61.4 (14.0) and mean (SD) CRTwas 448.4 (124.1)
μm for the overall patient population.
Visual acuity at 12 months
Change in mean (SD) BCVA from baseline was + 7.8 (12.3)
letters in the treatment-naïve cohort and + 5.0 (11.3) letters in
the previously treated cohort, whereas it was + 6.5 (11.9) let-
ters in the overall population (Fig. 2a). Change in mean (SD)
BCVA score in the subgroup of patients with ≥ 70 letters at
baseline was + 3.6 (7.4) for treatment-naïve patients (n = 24)
and + 1.9 (6.7) for previously treated patients (n = 16). Letter
gains and losses according to treatment cohort are shown in
Fig. 2 b. A greater proportion of treatment-naïve patients ex-
perienced letter gains than previously treated patients, whereas
the proportion of patients experiencing letter losses was sim-
ilar across all cohorts. Patients with lower BCVA letter score
at baseline reported the highest change in BCVA letter scores
at month 12 in both treatment cohorts compared with patients
with higher BCVA letter scores at baseline (Fig. 2c).
In the treatment-naïve cohort, change in mean (SD) BCVA
in patients receiving the full five initial doses (51.9%, n = 40)
within the first 5 months (i.e., within 150 + 15 days from the
first injection) was + 8.4 (13.8) letters compared with + 7.2
(10.4) letters in patients who did not receive the five initial
doses (48.1%, n = 37). Gains of ≥ 10 letters were achieved by
52.5% (n = 21) of patients receiving the five initial doses com-
pared with 37.8% (n = 14) who did not receive the five initial
doses. Gains of ≥ 15 letters were achieved in 35.0% (n = 14) of
patients receiving the five initial doses compared with 24.3%
(n = 9) of patients who did not receive the five initial doses.
Anatomic outcomes at month 12
At month 12, mean (SD) CRT decreased from 439.0 (120.3)
μm at baseline to 305.6 (94.3; total reduction − 129.5) μm in
treatment-naïve patients and from 459.7 (128.6) μm to 318.8
(105.0; total reduction − 137.6) μm in previously treated pa-
tients. When looking at the overall population, mean (SD)
CRT decreased from 448.4 (124.1) μm at baseline to 311.5
(99.1; total reduction − 133.2) μm at month 12. Mean change
in CRT over the course of 12 months and according to treat-
ment cohort is shown in Fig. 3.
At baseline, subretinal fluid (SRF) was observed in 30.3%
of treatment-naïve patients and 20.0% of previously treated
patients. At month 12, the proportion of patients with SRF
Enrolled patients, N=402
Included in the safety 
analysis, N=388
Patients excluded 
from the safety 
analysis, n=14
• No treatment injection in 
both eyes, n=14
Included in the full 
analysis set, N=374
Reason for exclusion from 
the full analysis set,a n=28
• No BCVA evaluation at 
baseline, n=18
• Screening failure, n=18
• No treatment injection in study 
eye, n=14
• Patient excluded from the safety 
set, n=14
Included in the 12 month 
interim analysis, N=147
Treatment-naïve, n=77 Previously treated, n=70
Fig. 1 Patient disposition. aA
patient could have multiple
reasons for exclusion. BCVA,
best-corrected visual acuity
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decreased to 5.5% in treatment-naïve and 4.7% in previously
treated patients. Baseline IRF was observed in ~ 95.0% of
patients in both treatment cohorts. At month 12, the proportion
of patients with IRF decreased to 67.1% of treatment-naïve
and 70.3% of previously treated patients.
Number of injections at month 12
Forty (51.9%) treatment-naïve patients, 22 (31.4%) previous-
ly treated patients, and 62 patients (42.2%) overall received
the five initial doses of IVT-AFL. Mean (SD) number of IVT-
AFL injections was 7.6 (2.5) in treatment-naïve patients, 7.6
(2.3) in previously treated patients, and 7.6 (2.4) in the overall
population. A total of 40 (51.9%) treatment-naïve patients, 36
(51.4%) previously treated patients, and 76 (51.7%) patients
in the overall population received ≤ 8 injections. The number
of injections based on BCVA score at baseline is shown in
Fig. 4. Mean number of injections at month 12 in the treat-
ment-naïve cohort increased with increasing baseline BCVA
letter scores. In the previously treated cohort, the mean (SD)
number of injections was higher in patients with < 24 BCVA
letter score at baseline compared with patients with > 24
BCVA letter score at baseline.
Safety analysis at month 12
Over the 12-month study period, 54.1% (n = 210) of patients
reported ocular TEAEs and 34.8% (n = 135) of patients







Age, years 65.2 (11.2) 66.5 (10.6) 65.8 (10.9)
Males (n (%)) 46 (59.7) 36 (51.4) 82 (55.8)
BMI (kg/m) 28.9 (6.4) 30.0 (5.4) 29.5 (5.9)
Median time since last DME treatment, months
(Q1–Q3)
– 3.1 (1.5–6.9) –
Anti-VEGF agent (n (%) [n = 47])
Ranibizumaba (n (%)) – 44 (93.6) –
Median ranibizumab treatment duration,
months (Q1–Q3)
– 6.2 (2.3–20.4) –
Mean number of ranibizumab injections
received (n = 45)
– 8.8 (7.5) –
Photocoagulation lasera (n (%) [n = 68]) – 41 (60.3) –
Metabolic characteristics
Systolic blood pressure (mmHg) 143.3 (22.4) 139.6 (19.0) 141.2 (20.5)
Diastolic blood pressure (mmHg) 75.7 (13.4) 77.8 (9.1) 76.9 (11.1)
HbA1c (%) 7.9 (1.5) 7.5 (1.3) 7.7 (1.4)
Diabetes (n (%))
Type 1 12 (15.6) 8 (11.6) 20 (13.7)
Type 2 65 (84.4) 61 (88.4) 126 (86.3)
Median time since DME diagnosis, months
(Q1–Q3)
1.0 (0.3; 2.8) 23.8 (11.3; 41.6) 8.6 (0.8;
28.5)
Visual and anatomic outcomes
BCVA, letters 62.7 (14.3) 60.0 (13.7) 61.4 (14.0)
≤24 letters (n (%)) 2 (2.6) 2 (2.9) 4 (2.7)
24–70 letters (n (%)) 51 (66.2) 52 (74.3) 103 (70.1)
≥ 70 letters (n (%)) 24 (31.2) 16 (22.9) 40 (27.2)
CRT (μm) 439.0 (120.3) 459.7 (128.6) 448.4
(124.1)
Subretinal fluid visible on OCT (n (%)) 23 (30.3) 13 (20.0) 36 (25.5)
Intraretinal fluid visible on OCT (n (%)) 72 (94.7) 64 (95.5) 136 (95.1)
Data are reported as mean (SD) unless otherwise stated and are for those who received an assessment
a Patients previously treated with the indicated treatment. A patient may have received several previous treatments
for DME
BCVA best-corrected visual acuity, BMI body mass index, CRT central retinal thickness, DME diabetic macular
edema, HbA1c haemoglobin A1C, OCT optical coherence tomography, Q quartile, SD standard deviation, VEGF
anti-vascular endothelial growth factor
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reported ocular TEAEs that were deemed to be related to IVT-
AFL treatment. The most commonly (≥ 2.0%) observed
ocular TEAEs were cataract (4.4%, n = 17), diabetic retinal
edema (recurrence or aggravation, 3.1%, n = 12), visual acuity
reduced (2.8%, n = 11), and macular edema (recurrence,
2.3%, n = 9). Two cases of endophthalmitis were also report-
ed. A list of safety events is reported in Table 2. Treatment
withdrawal due to ocular TEAEs occurred in 0.8% (n = 3) of
patients. Serious ocular TEAEs occurred in 2.8% (n = 11) of
patients. One serious ocular TEAE (vitreous detachment) in
one patient was deemed to be related to IVT-AFL treatment.
Three deaths (0.8%) occurred and were assessed to be not
related to study drug.
Discussion
This 12-month interim analysis of the APOLLON study
showed that IVT-AFL injections were associated with
functional and anatomic benefits in French private and
public clinical practice, which was consistent with re-
sults observed in randomised controlled trials (VIVID,
mean change in BCVA score at 12 months was + 10.7
letters) and other real-world studies (Moorfields’ real-
world study, mean change in BCVA score at 12 months
was + 9.9 letters) [7, 9]. Visual gains observed in the
APOLLON study were particularly meaningful given
that more than 60% of patients had baseline BCVA
letter score ≥ 60, and eyes with better baseline vision
have less potential to gain letters than eyes with poorer
baseline vision [10].
In this study, treatment-naïve patients achieved better
visual outcomes than previously treated patients, even
though mean baseline BCVA letter scores were similar
between the two treatment cohorts. One possibility for
the outcomes of the current interim analysis is that treat-
ment-naïve patients received earlier and more effective
care compared with previously treated patients, and did
not have other conditions, such as chronic macular ede-
ma. Moreover, patients who were refractory to previous
treatments were also included in the previously treated
cohort, and this patient subgroup might have had a lower
response to IVT-AFL treatment than non-refractory pre-
viously treated patients. Further investigations are re-
quired to evaluate if the switch to IVT-AFL was benefi-
cial in this patient subgroup; however, this is beyond the
scope of the present analysis.
In our study, both patient cohorts experienced im-
provements in anatomic outcomes and a decline in both
SRF and IRF following IVT-AFL treatment. Previous
studies found that the presence of SRF was associated
with likelihood of treatment response [11]; however, if
left untreated, SRF may be detrimental in the long term,
whereas IRF is associated with poor visual acuity and is






























































































































Fig. 2 a Visual acuity gains from baseline to month 12. Numbers on top
of columns indicate mean change in BCVA letter score (SD) from base-
line to month 12. b Letter gains and losses based on treatment cohort. c
Change in mean BCVA letter score from baseline to month 12 based on
treatment cohort and baseline BCVA letter score. BCVA, best-corrected
visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; SD,
standard deviation
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observed in APOLLON may provide additional benefits
hereafter. However, an important proportion of patients
in both treatment cohorts had residual IRF at month 12
despite receiving several intra- and inter-class treatments,
which may correspond to time of recurrence in some
patients under different treatment regimens, and high-
lights the current challenges faced by ophthalmologists
in providing effective care to patients with DME.
Treatment of DME with IVT-AFL is indicated to be
initiated with five consecutive monthly injections,
followed by one injection every ~ 2 months [12].
Adoption of a regimen that includes the five initial
IVT-AFL doses has been beneficial in improving visual
outcomes in patients with DME [13]. In the patient
cohort of the present analysis, a greater proportion of
treatment-naïve patients than of previously treated pa-
tients received the five initial IVT-AFL doses and adop-
tion of this regimen may have contributed to greater
improvements in visual outcomes. Previously treated pa-
tients might have missed the five initial doses based on
the physician’s decision to switch to IVT-AFL from
other anti-VEGF agents without starting the indicated
initiation protocol. Despite this difference, the total
mean number of injections was similar between treat-










































Fig. 3 Mean CRT change across
12 months and according to
treatment cohort. CRT, central
retinal thickness
Table 2 Summary of main safety events (safety analysis set)
N = 388 (n (%))
Most common AEs (> 5.0%)
Inappropriate schedule of drug administration 174 (44.8)
Product use issue 75 (19.3)
Off label use 24 (6.2)
Any ocular TEAE 210 (54.1)
Any ocular TEAE (> 1.0%)
Cataract 17 (4.4)
Diabetic retinal edema 12 (3.1)
Visual acuity reduced 11 (2.8)
Macular edema 9 (2.3)
Vitreous floaters 7 (1.8)
Ocular hypertension 5 (1.3)
Any treatment-related ocular TEAE 135 (34.8)
Any serious ocular TEAE 11 (2.8)
Any serious treatment-related ocular TEAE 1 (0.3)
Any non-ocular TEAE 178 (45.9)
Any ocular TEAE leading to discontinuation 3 (0.8)
Any treatment-related non-ocular TEAE 110 (28.4)
Any serious non-ocular TEAE 49 (12.6)
Any serious treatment-related non-ocular TEAE 2 (0.5)
Any non-ocular TEAE leading to discontinuation 6 (1.5)
There were no serious AEs > 2%





























(n=2) (n=51) (n=24)(n=2) (n=52) (n=16)
≤24 24–70 ≥70
Baseline BCVA letters
Fig. 4 Number of injections received per BCVA letter score at baseline
and treatment cohort over 12 months. BCVA, best-corrected visual acuity
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lower BCVA letter scores at baseline tended to receive
more injections than treatment-naïve patients in the cor-
responding BCVA letter score subgroup. When compar-
ing real-world with randomised controlled trials, the
overall number of injections in APOLLON was lower
than that reported in VIVID (7.6 vs 8.7, respectively)
[7]; however, a fixed-dosing regimen was adopted in
VIVID, whereas the adopted IVT-AFL regimens in
APOLLON might have been more variable and interpre-
tation of these results warrants caution. In terms of safe-
ty, the incidence of adverse events in the APOLLON
study was consistent with the known safety profile of
anti-VEGF agents, with cataract and diabetic retinal ede-
ma being the most common ocular events.
This study had some limitations as observational studies
are subject to recruitment and practice biases (visual acuity
measurements are not standardised). Other limitations include
its small size and the fact that these findings were not adjusted
for confounders, such as age and disease severity. Strengths of
this study include the prospective design and that patient co-
horts were well defined.
In conclusion, this interim analysis of the APOLLON
study showed that IVT-AFL for the treatment of DME
was associated with improved functional and anatomic
outcomes. In addition, treatment-naïve patients showed a
trend toward better visual and anatomic improvements
than those observed in previously treated patients, sug-
gesting that early and effective treatment may prevent
irreversible vision loss.
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